BRPI0415695A - agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas - Google Patents
agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogasInfo
- Publication number
- BRPI0415695A BRPI0415695A BRPI0415695-1A BRPI0415695A BRPI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A
- Authority
- BR
- Brazil
- Prior art keywords
- tuberculosis
- drugs
- combined treatment
- immunotherapeutic agent
- combination
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000002955 immunomodulating agent Substances 0.000 title abstract 3
- 201000008827 tuberculosis Diseases 0.000 title abstract 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"AGENTE IMUNOTERáPICO úTIL PARA O TRATAMENTO COMBINADO DE TUBERCULOSE EM ASSOCIAçãO COM OUTRAS DROGAS". Refere-se a presente invenção a um agente imunoterápico baseado em fragmentos das paredes celulares de linhagens virulentas de Mycobacterium tuberculosis, a um método para a obtenção deste agente imunoterápico, às formulações farmacêuticas que o contém e a sua utilização para a preparação de uma droga para o tratamento combinado de tuberculose em associação com outras drogas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200302551A ES2231037B1 (es) | 2003-10-31 | 2003-10-31 | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
PCT/ES2004/000482 WO2005042013A1 (es) | 2003-10-31 | 2004-10-29 | Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0415695A true BRPI0415695A (pt) | 2006-12-26 |
BRPI0415695A8 BRPI0415695A8 (pt) | 2019-01-15 |
BRPI0415695B1 BRPI0415695B1 (pt) | 2019-09-10 |
BRPI0415695B8 BRPI0415695B8 (pt) | 2021-05-25 |
Family
ID=34530979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415695A BRPI0415695B8 (pt) | 2003-10-31 | 2004-10-29 | agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas |
Country Status (21)
Country | Link |
---|---|
US (1) | US8246944B2 (pt) |
EP (1) | EP1690549B1 (pt) |
JP (1) | JP4998988B2 (pt) |
KR (1) | KR101146469B1 (pt) |
CN (1) | CN100490894C (pt) |
AT (1) | ATE428442T1 (pt) |
AU (1) | AU2004285305B2 (pt) |
BR (1) | BRPI0415695B8 (pt) |
CA (1) | CA2543659C (pt) |
DE (1) | DE602004020663D1 (pt) |
DK (1) | DK1690549T3 (pt) |
ES (2) | ES2231037B1 (pt) |
HK (1) | HK1098362A1 (pt) |
IL (1) | IL175030A (pt) |
MA (1) | MA28121A1 (pt) |
NZ (1) | NZ546715A (pt) |
PL (1) | PL1690549T3 (pt) |
PT (1) | PT1690549E (pt) |
RU (1) | RU2341287C2 (pt) |
WO (1) | WO2005042013A1 (pt) |
ZA (1) | ZA200604234B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2231037B1 (es) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
EP2027865A4 (en) * | 2006-05-12 | 2010-08-18 | Univ Hokkaido Nat Univ Corp | LIPOSOME HAVING A LIPIDIC MEMBRANE CONTAINING A BACTERIAL CELLULAR COMPONENT |
ES2307402B1 (es) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | Vacuna profilactica contra la tuberculosis. |
ES2335177B1 (es) * | 2008-09-19 | 2011-02-28 | Archivel Farma, S.L. | Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis. |
EP2471511A1 (en) | 2011-01-04 | 2012-07-04 | Archivel Farma, SL | Liposome formulation suitable for treating or preventing tuberculosis |
WO2012093137A1 (en) * | 2011-01-04 | 2012-07-12 | Archivel Farma, Sl | Liposome formulation suitable for treating or preventing tuberculosis |
EP2802345B1 (en) | 2012-01-12 | 2018-03-07 | Archivel Farma, S.l. | Mtb-c vaccine against allergic responses |
ES2758400B2 (es) | 2018-11-02 | 2021-01-20 | Univ Granada | Nanoparticulas biomimeticas mediadas por mamc |
WO2023062066A1 (en) | 2021-10-14 | 2023-04-20 | Archivel Farma, S.L. | Liposome formulations for treatment of active tuberculosis |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3125598A1 (de) * | 1981-06-30 | 1983-01-13 | Mahle Gmbh, 7000 Stuttgart | Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine |
JPS59161320A (ja) * | 1983-03-04 | 1984-09-12 | Maruyama Chisato | リポ多糖体およびその製造法 |
GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
JPS624701A (ja) * | 1985-06-29 | 1987-01-10 | Maruyama Chisato | リポ多糖体及びその製造法 |
US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
US5785975A (en) * | 1995-06-26 | 1998-07-28 | Research Triangle Pharmaceuticals | Adjuvant compositions and vaccine formulations comprising same |
US6284255B1 (en) | 1996-08-29 | 2001-09-04 | Genesis Research & Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
CA2346218A1 (en) * | 1998-10-08 | 2000-04-20 | Statens Serum Institut | Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell |
RU2153354C1 (ru) * | 1999-03-31 | 2000-07-27 | Московский городской научно-практический центр борьбы с туберкулезом | Вакцина против туберкулеза |
AU2002239485A1 (en) * | 2000-12-08 | 2002-06-18 | The Johns Hopkins University | Methods for improved diagnosis and treatment of mycobacterial infections |
JP3944452B2 (ja) * | 2001-01-08 | 2007-07-11 | アメリカ合衆国 | 潜伏性ヒト結核モデル、診断用抗原、および使用法 |
EP1379529A2 (en) * | 2001-03-16 | 2004-01-14 | Sarawak Medichem Pharmaceuticals, Inc. | Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity |
US7393540B2 (en) | 2001-07-04 | 2008-07-01 | Health Protection Agency | Mycobacterial antigens expressed during latency |
WO2003018053A1 (en) | 2001-08-22 | 2003-03-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccine against mycobacterial-induced diseases |
CA2474794A1 (en) | 2002-01-29 | 2003-08-07 | Modi, Rajiv Indravadan | Method of providing prophylaxis for tuberculosis in hiv positive individuals |
ES2231037B1 (es) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
DE102004053141A1 (de) * | 2004-11-03 | 2006-05-04 | Schülke & Mayr GmbH | Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien |
-
2003
- 2003-10-31 ES ES200302551A patent/ES2231037B1/es not_active Expired - Fee Related
-
2004
- 2004-10-29 RU RU2006118795/13A patent/RU2341287C2/ru active
- 2004-10-29 EP EP04791401A patent/EP1690549B1/en active Active
- 2004-10-29 DE DE602004020663T patent/DE602004020663D1/de active Active
- 2004-10-29 US US10/577,840 patent/US8246944B2/en active Active
- 2004-10-29 BR BRPI0415695A patent/BRPI0415695B8/pt active IP Right Grant
- 2004-10-29 JP JP2006537326A patent/JP4998988B2/ja not_active Expired - Fee Related
- 2004-10-29 WO PCT/ES2004/000482 patent/WO2005042013A1/es active Application Filing
- 2004-10-29 CN CNB2004800322762A patent/CN100490894C/zh active Active
- 2004-10-29 DK DK04791401T patent/DK1690549T3/da active
- 2004-10-29 AT AT04791401T patent/ATE428442T1/de not_active IP Right Cessation
- 2004-10-29 KR KR1020067008014A patent/KR101146469B1/ko active IP Right Grant
- 2004-10-29 NZ NZ546715A patent/NZ546715A/en unknown
- 2004-10-29 PT PT04791401T patent/PT1690549E/pt unknown
- 2004-10-29 PL PL04791401T patent/PL1690549T3/pl unknown
- 2004-10-29 CA CA2543659A patent/CA2543659C/en active Active
- 2004-10-29 ES ES04791401T patent/ES2325835T3/es active Active
- 2004-10-29 AU AU2004285305A patent/AU2004285305B2/en not_active Ceased
-
2006
- 2006-04-20 IL IL175030A patent/IL175030A/en active IP Right Grant
- 2006-04-28 MA MA28985A patent/MA28121A1/fr unknown
- 2006-05-25 ZA ZA200604234A patent/ZA200604234B/en unknown
-
2007
- 2007-05-04 HK HK07104774.7A patent/HK1098362A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1098362A1 (en) | Immunotherapic agent which is used for the combined treatment of tuberculosis togetheir with other pharmaceuticals | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
BRPI0408655A (pt) | formulações compreendendo um agente ativo e cacau em pó e a sua utilização | |
BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
CY1114863T1 (el) | Στερεο παρασκευασμα | |
BRPI0410249A (pt) | moléculas que melhoram a distribuição dérmica de vacinas contra influenza | |
BR0008699A (pt) | Combinações de formoterol e furoato demometasona para asma | |
BR0114786A (pt) | Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição | |
BR9815255A (pt) | Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal | |
BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
BR0309390A (pt) | Composição farmacêutica | |
BRPI0415986A (pt) | método e aparelho para reduzir a incidência do uso de tabaco | |
BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
HUP0202537A2 (hu) | Vakcinakészítmény és eljárás annak alkalmazására | |
NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
BRPI0414979A (pt) | preparação sólida | |
BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
NO20052216L (no) | Smertestillende midler | |
WO2004014367A3 (en) | Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
HUP9700806A2 (hu) | Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására | |
BR0110512A (pt) | Preparação para medir a taxa de esvaziamento gástrico | |
GB2423927A (en) | Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome | |
BRPI0409387B8 (pt) | complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |